Results 11 to 20 of about 4,256 (179)

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors

International Journal of Molecular Sciences, 2022
Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic regulation in diabetes. In addition to their glucose-lowering effects, SGLT2 inhibitors prevent both renal damage and the onset of chronic kidney disease and cardiovascular ...
Celestino Sardu, Alfredo Caturano, TERESA Salvatore   +2 more
exaly   +3 more sources

Role of the Natriuretic Peptide System in Cardiorenal Protection [PDF]

Archives of Internal Medicine, 2003
Significant progress has been made in the understanding of the neurohormonal factors that contribute to the progression of chronic renal and cardiac failure and the development of target-organ damage in patients with hypertension and diabetes. We herein review some of these advances, including a new therapeutic strategy for potentially enhancing ...
James Sowers, Nathaniel Winer
exaly   +3 more sources

GLP-1-based therapeutics for cardiorenal protection in metabolic diseases. [PDF]

Nephrol Dial Transplant
ABSTRACT Over the last decade, significant progress has been made in cardiorenal protection for metabolic diseases such as type 2 diabetes (T2D) and obesity. With an expanding range of pharmacological options and continuously evolving guidelines, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered substantial clinical ...
Apperloo EM, Heerspink HJL, van Raalte DH, Muskiet MHA.   +3 more
europepmc   +4 more sources

Overcoming Hyperkalaemia as a Barrier to Achieving Optimal RAASi Therapy and Cardiorenal Protection in Individuals with Cardiorenal Disease: A Podcast Discussion. [PDF]

Adv Ther
Renin-angiotensin-aldosterone system inhibitor (RAASi) therapies are a cornerstone of guideline-directed medical therapy in the management of cardiorenal disease, including chronic kidney disease and heart failure. Management guidelines state that these therapies should be prescribed at the maximum licensed or tolerated dose in order to prevent disease
Frankel AH, Bramham K, Byrne B, Chiu G, Chumber R, Davies SJ, Fuat A, Gray L, Green D, Priestman W, Welch M, Williams SG, Wheatcroft S.   +12 more
europepmc   +6 more sources

Cardiorenal Protective Effect of Costunolide against Doxorubicin-Induced Toxicity in Rats by Modulating Oxidative Stress, Inflammation and Apoptosis

Molecules, 2022
Doxorubicin (DXB) is one of the most commonly used anticancer agents for treating solid and hematological malignancies; however, DXB-induced cardiorenal toxicity presents a limiting factor to its clinical usefulness in cancer patients. Costunolide (COST)
Wen Xing, Chaoling Wen, Deguo Wang, Hui Shao, Chunhong Liu, Chunling He, Opeyemi Joshua Olatunji   +6 more
doaj   +3 more sources

Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i

Renal Failure
Objectives Chronic cardiorenal syndrome (types 2 and 4) arises from chronic dysfunction of either the heart or kidneys, leading to progressive deterioration of the other organ.
Yixin Zhu, Chenxi Lv, Hanqi Yang, Qian Lu, XuChen Wang, Yueqi Zhang, Maojuan Guo, Bo Yang   +7 more
doaj   +4 more sources

Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU) [PDF]

BMJ Open
Introduction Patients discharged from intensive care units (ICUs) are at high risk of adverse long-term outcomes including cardiovascular and/or renal events and a 1-year mortality of approximately 22%.
Eric Vicaut, Thomas Kerforne, Marc Garnier, Alexandre Mebazaa, Jean-Pierre Quenot, Anne-Claire Lukaszewicz, Kada Klouche, Agathe Delbove, Quentin Levrat, Pierre Asfar, Antoine Kimmoun, Belaid Bouhemad, Hamid Merdji, Wulfran Bougouin, Stephane Legriel, Alexandre Ouattara, Emmanuelle Rouve, Benjamin Chousterman, Emanuele Turbil, Claire Roger, François Dépret, Robin Lalande, Marion Jully   +22 more
doaj   +2 more sources

Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists. [PDF]

Adv Chronic Kidney Dis, 2021
The worldwide prevalence of type 2 diabetes (T2D) is steadily increasing, and it remains a challenging public health problem for populations in both developing and developed countries around the world. Despite the recent advances in novel antidiabetic agents, diabetic kidney disease and cardiovascular disease remain the leading causes of morbidity and ...
Tommerdahl KL, Nadeau KJ, Bjornstad P.
europepmc   +3 more sources

Beyond glycemic control: SGLT2 inhibitors as time-sensitive organ-protective agents in acute injury—mechanistic insights and translational implications [PDF]

Frontiers in Pharmacology
BackgroundSodium-glucose cotransporter 2 inhibitors (SGLT2is) were initially developed as glucose-lowering therapies for type 2 diabetes mellitus. However, large cardiovascular and renal outcome trials have demonstrated rapid reductions in heart failure ...
Ji Wu, Yaozheng Cai, Jiangtao Chen, Qian Zang, Ping Zhu, Yueping Ding   +5 more
doaj   +2 more sources

The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3 [PDF]

Diabetes Care, 2023
Vikas Srinivasan Sridhar, Hiddo Lambers Heerspink, David Cherney   +2 more
exaly   +2 more sources